目的: 探讨微小核糖核酸-1246(miR-1246)和核因子I/B(NFIB)在肝癌组织中的表达水平, 分析二者与预后的关系。方法: 纳入我院2017年3月至2019年3月收治的肝癌患者160例, 均获得癌组织及癌旁组织, 检测癌组织、癌旁组织中miR-1246和NFIB的表达情况, 分析二者与临床病理特征的关系。根据患者24个月的累积生存情况分成生存组、死亡组, 比较两组癌组织中miR-1246、NFIB表达情况, 经Cox多元回归模型分析预后的危险因素。结果: 肝癌组织中miR-1246表达量高于癌旁组织, NFIB高表达率高于癌旁组织(P < 0.05)。miR-1246、NFIB高表达组临床分期Ⅲ期、肿瘤直径≥5 cm、多发性肿瘤比例高于低表达组, 且NFIB高表达组ALT > 40 U·L^-1比例高于低表达组(P < 0.05)。生存组miR-1246、NFIB高表达率低于死亡组(P < 0.05)。Cox多元回归分析显示临床分期Ⅲ期、肿瘤直径≥5 cm、多发性肿瘤以及miR-1246、NFIB高表达是预后的危险因素(P < 0.05)。结论: 肝癌组织中miR-1246表达量以及NFIB高表达率较癌旁组织增高, 二者对患者预后影响较大, 有望成为评估预后的指标。

[1] YU L X, SCHWABE R F. The gut microbiome and liver cancer: mechanisms and clinical translation[J]. Nat Rev Gastro Hepat, 2017, 14(9): 527-539.
[2] LUNA J M, BARAJAS J M, TENG K Y, et al. Argonaute CLIP defines a deregulated miR-122-bound transcriptome that correlates with patient survival in human liver cancer[J]. Mol Cell, 2017, 67(3): 400-410.
[3] 张春雨, 付宇, 李晓东, 等. 肝癌的影像学诊断进展[J]. 临床肝胆病杂志, 2017, 33(7): 1266-1269.
[4] TAO J Y, JIANG L L, CHEN X. Roles of microRNA in liver cancer[J]. Liver Res, 2018, 2(2): 61-72.
[5] 王明, 夏彦民, 王文辰, 等. miR-1246通过靶向GSK3β促进食管癌转移的机制[J]. 现代肿瘤医学, 2017, 9(17): 36-41.
[6] 冯一鸣, 姚德生, 卢艳, 等. 宫颈鳞癌患者血清miR-1246的表达及其临床意义[J]. 肿瘤防治研究, 2019, 46(6): 532-536.
[7] ZHOU Z H, MAO L H, LI X Q, et al. 868— The role of nuclear factor nfib-mediated nad metabolism reprogramming in the development and progression of colorectal cancer[J]. Gastroenterology, 2019, 156(6): S194-S195.
[8] 陈杰. 病理诊断免疫组化手册[M]. 北京: 中国协和医科大学出版社, 2014: 77.
[9] WU J, YANG S, XU K, et al. Patterns and trends of liver cancer incidence rates in Eastern and Southeastern Asian Countries (1983—2007) and predictions to 2030[J]. Gastroenterology, 2018, 154(6): 1719-1728.
[10] 万思哲, 朱萱. RhoA对肝癌进展的调节作用机制[J]. 中国生物化学与分子生物学报, 2019, 35(5): 480-485.
[11] 舒耀, 吴斌, 宋俊. 乳腺癌患者血清中miRNA-21、miRNA-210、miRNA-1246的表达及临床意义[J]. 中国现代医学杂志, 2018, 28(12): 42-48.
[12] SALAH M, SHAHEEN I, EL-SHANAWANY P, et al. Detection of miR-1246, miR-23a and miR-451 in sera of colorectal carcinoma patients: a case-control study in Cairo University Hospital[J]. Afr Health Sci, 2020, 20(3): 1283-1291.
[13] CAMPBELL T M, CASTRO M A, DEOLIVEIRA K G, et al. ER alpha binding by transcription factors NFIB and YBX1 enables FGFR2 signalling to modulate estrogen responsiveness in breast cancer[J]. Cancer Res, 2017, 78(2): 410-421.
[14] 王倩, 徐庆丽, 李艳华, 等. miR-1246增强宫颈癌细胞辐射敏感性的分子机制研究[J]. 中国病理生理杂志, 2018, 34(11): 77-84.
[15] 胡煜, 王玲, 毕武, 等. miR-1246在疾病上的研究进展[J]. 生物技术通报, 2017, 33(3): 29-36.
[16] BHAGIRATH D, YANG T L, BUCAY N, et al. MicroRNA-1246 is an exosomal biomarker for aggressive prostate cancer[J]. Cancer Res, 2018, 78(7): 1833-1844.
[17] XU Y F, HANNAFON B N, KHATRI U, et al. The origin of exosomal miR-1246 in human cancer cells[J]. RNA Biol, 2019, 16(6): 770-784.
[18] LIU R Z, VO T M, JAIN S, et al. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer: Role of NFIB in breast cancer cell survival[J]. J Pathol, 2018, 247(2): 186-198.
[19] BECKER-SANTOS D, MINATEL B, LONERGAN K, et al. MA02.03 Expression of oncofetal miRNAs inactivates NFIB, a developmental transcription factor linked to tumor aggressiveness in lung adenocarcinoma[J]. J Thorac Oncol, 2017, 12(1): S349-S350.
[20] AFSHARI M K, FEHR A, NEVADO P T, et al. Activation of PLAG1 and HMGA2 by gene fusions involving the transcriptional regulator gene NFIB[J]. Gene Chromosome Canc, 2020, 59(1): 652-660.
[21] YANG F, XIONG H, DUAN L, et al. MiR-1246 promotes metastasis and invasion of A549 cells by targeting GSK-3β mediated Wnt/β-catenin pathway[J]. Cancer Res Treat, 2019, 51(4): 1420-1429.
[22] WU C, ZHU X, LIU W, et al. NFIB promotes cell growth, aggressiveness, metastasis and EMT of gastric cancer through the Akt/Stat3 signaling pathway[J]. Oncol Rep, 2018, 40(3): 1565-1573.
[23] ZHANG D G, XU H W, WANG Y Q, et al. 125I radiation downregulates TRPV1 expression through miR-1246 in neuroblastoma cells[J]. Oncol Rep, 2019, 42(1): 243-252.
[24] 何运, 罗嘉, 陈攀, 等. 原发性肝癌患者1838例预后因素分析[J]. 肿瘤学杂志, 2017, 23(9): 789-793.
[25] 王华利, 熊清芳, 杨永峰. 279例老年原发性肝癌临床特点及预后影响因素分析[J]. 实用老年医学, 2017, 31(12): 1135-1137.